Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	4 April 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) Alexandra Elizabeth Yatomi-Clarke
Date of change	1 May 2023

No. of securities held prior to change	**Direct** 4,641,711 Fully paid ordinary shares 3,500,000 Unlisted Options, exercisable at $0.0663 (6.63 cents) per option, expiring on 2 May 2023 **Indirect** *Arrow Wealth Ltd* 3,245,000 Fully paid ordinary shares *Novetera Pty Ltd* 1,986,870 Fully paid ordinary shares 12,900,000 Unlisted Options, exercisable at $0.0968 (9.68 cents) per option, expiring on 23 November 2024 *Alexandra Elizabeth Yatomi-Clarke* 172,500 Fully paid ordinary shares
Class	(a) Fully Paid Ordinary Shares (b) Unlisted Options, exercisable at $0.0633 (6.63 cents) per option, expiring on 2 May 2023
Number acquired	(a) 1,148,936 (b) Nil
Number disposed	(a) Nil (b) 2,351,064
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (Options exercised pursuant to cashless exercise facility)
No. of securities held after change	**Direct** 5,790,647 Fully paid ordinary shares **Indirect** *Arrow Wealth Ltd* 3,245,000 Fully paid ordinary shares *Novetera Pty Ltd* 1,986,870 Fully paid ordinary shares 12,900,000 Unlisted Options, exercisable at $0.0968 (9.68 cents) per option, expiring on 23 November 2024 *Alexandra Elizabeth Yatomi-Clarke* 172,500 Fully paid ordinary shares

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares upon the exercise of options utilising a cashless exercise facility

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Engle
Date of last notice	17 December 2020

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	1 May 2023
No. of securities held prior to change	670,000 Unlisted options exercisable at $0.0663 (6.63 cents) per option, expiring on 2 May 2023 2,100,000 Unlisted options exercisable at $0.0968 (9.68 cents) per option, expiring on 23 November 2024
Class	(a) Fully Paid Ordinary Shares (b) Unlisted Options, exercisable at $0.0633 (6.63 cents) per option, expiring on 2 May 2023
Number acquired	(a) 219,939 (b) Nil
Number disposed	(a) Nil (b) 450,061
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (Options exercised pursuant to cashless exercise facility)

No. of securities held after change	219,939 Fully Paid Ordinary Shares 2,100,000 Unlisted options exercisable at $0.0968 (9.68 cents) per option, expiring on 23 November 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares upon the exercise of options utilising a cashless exercise facility

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder **(if issued securities)**	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	4 April 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Fusion Biosciences Pty Ltd (Director and Beneficiary)
Date of change	1 May 2023
No. of securities held prior to change	**Direct** 260,134 Fully Paid Ordinary Shares 415,000 Unlisted Options, exercisable at $0.0633 (6.63 cents) per option, expiring on 2 May 2023 **Indirect** *Fusion Biosciences Pty Ltd* 1,000,000 Unlisted Options, exercisable at $0.0968 (9.68 cents) per option, expiring on 23 November 2024
Class	(a) Fully Paid Ordinary Shares (b) Unlisted Options, exercisable at $0.0633 (6.63 cents) per option, expiring on 2 May 2023

+ See chapter 19 for defined terms.

Number acquired	(a) 136,231 (b) Nil
Number disposed	(a) Nil (b) 278,769
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (Options exercised pursuant to cashless exercise facility)
No. of securities held after change	**Direct** 396,365 Fully Paid Ordinary Shares **Indirect** *Fusion Biosciences Pty Ltd* 1,000,000 Unlisted Options, exercisable at $0.0968 (9.68 cents) per option, expiring on 23 November 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares upon the exercise of options utilising a cashless exercise facility

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder **(if issued securities)**	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.